<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>21(18)</volume><submitter>Klafki HW</submitter><pubmed_abstract>The ratio of amyloid precursor protein (APP)669-711 (Aβ-3-40)/Aβ1-42 in blood plasma was reported to represent a novel Alzheimer's disease biomarker. Here, we describe the characterization of two antibodies against the N-terminus of Aβ-3-x and the development and "fit-for-purpose" technical validation of a sandwich immunoassay for the measurement of Aβ-3-40. Antibody selectivity was assessed by capillary isoelectric focusing immunoassay, Western blot analysis, and immunohistochemistry. The analytical validation addressed assay range, repeatability, specificity, between-run variability, impact of pre-analytical sample handling procedures, assay interference, and analytical spike recoveries. Blood plasma was analyzed after Aβ immunoprecipitation by a two-step immunoassay procedure. Both mono</pubmed_abstract><journal>International journal of molecular sciences</journal><pagination>E6564</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7555726</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Development and Technical Validation of an Immunoassay for the Detection of APP669-711 (Aβ-3-40) in Biological Samples.</pubmed_title><pmcid>PMC7555726</pmcid><pubmed_authors>Klafki HW</pubmed_authors><pubmed_authors>Beyer I</pubmed_authors><pubmed_authors>Jahn O</pubmed_authors><pubmed_authors>Knolker HJ</pubmed_authors><pubmed_authors>Vogelgsang J</pubmed_authors><pubmed_authors>Wiltfang J</pubmed_authors><pubmed_authors>Matzen A</pubmed_authors><pubmed_authors>Zampar S</pubmed_authors><pubmed_authors>Rohdenburg L</pubmed_authors><pubmed_authors>Oberstein TJ</pubmed_authors><pubmed_authors>Lachmann I</pubmed_authors><pubmed_authors>Rieper P</pubmed_authors><pubmed_authors>Wirths O</pubmed_authors><pubmed_authors>Osterloh D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development and Technical Validation of an Immunoassay for the Detection of APP669-711 (Aβ-3-40) in Biological Samples.</name><description>The ratio of amyloid precursor protein (APP)669-711 (Aβ-3-40)/Aβ1-42 in blood plasma was reported to represent a novel Alzheimer's disease biomarker. Here, we describe the characterization of two antibodies against the N-terminus of Aβ-3-x and the development and "fit-for-purpose" technical validation of a sandwich immunoassay for the measurement of Aβ-3-40. Antibody selectivity was assessed by capillary isoelectric focusing immunoassay, Western blot analysis, and immunohistochemistry. The analytical validation addressed assay range, repeatability, specificity, between-run variability, impact of pre-analytical sample handling procedures, assay interference, and analytical spike recoveries. Blood plasma was analyzed after Aβ immunoprecipitation by a two-step immunoassay procedure. Both mono</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Sep</publication><modification>2025-04-06T12:18:55.912Z</modification><creation>2020-10-29T10:51:11Z</creation></dates><accession>S-EPMC7555726</accession><cross_references><pubmed>32911706</pubmed><doi>10.3390/ijms21186564</doi></cross_references></HashMap>